Home » Stocks » MATN

Mateon Therapeutics Inc. (MATN)

Stock Price: $0.3350 USD 0.0050 (1.52%)
Updated Jan 22, 2021 3:59 PM EST - Market closed
Market Cap 30.02M
Revenue (ttm) 1.74M
Net Income (ttm) -9.54M
Shares Out 89.60M
EPS (ttm) -0.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $0.3350
Previous Close $0.3300
Change ($) 0.0050
Change (%) 1.52%
Day's Open 0.3260
Day's Range 0.3200 - 0.3500
Day's Volume 403,319
52-Week Range 0.08 - 0.35

News

Hide News
GlobeNewsWire - 1 week ago

AGOURA HILLS, California, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, reported po...

GlobeNewsWire - 3 weeks ago

AGOURA HILLS, Calif., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB:MATN) announced today that it has enrolled and treated its first sentinel P...

About MATN

Mateon Therapeutics, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment... [Read more...]

Industry
Biotechnology
IPO Date
Aug 26, 1993
CEO
Dr. Vuong Trieu
Employees
13
Stock Exchange
OTCMKTS
Ticker Symbol
MATN
Full Company Profile

Financial Performance

Financial Statements